[1]
Langley, R.G., Crowley, J., Gooderham, M., Papp, K.A., Korman, N.J., Spelman, L., Igarashi, A., Ohtsuki, M., Gupta, A.K., Yamauchi, P., Parno, J., Mendelsohn, A.M., Rozzo, S.J. and Eads, K. 2020. Efficacy and Safety of Long-Term Tildrakizumab for Plaque Psoriasis: 4-Year Results from Resurface 1 and Resurface 2. SKIN The Journal of Cutaneous Medicine. 4, 5 (Sep. 2020), s39. DOI:https://doi.org/10.25251/skin.4.supp.39.